HNPCC (Colon Cancer)

Hunter Payne

HNPCC Paper Outline

1) Epidemiology

a. Distribution by controllable factors such as obesity and carcinogen exposure

b. Distribution by uncontrollable factors such as sex, race and age

2) Common mutations

a. MSH2/EPCAM mutation (HNPCC1, approximately 60% of cases)

b. MLH1 mutation (HNPCC2, approximately 30% of cases)

c. MSH6 mutation (HNPCC5, approximately 8% of cases)

d. PMS2 mutation (HNPCC4, less than 2% of cases)

3) Treatment

a. General chemotherapy (FOLFOX and CapeOx)

b. Immunotherapies

i. Keytruda and Opdivo (PD-1 blockers)

ii. Yervoy (CTLA-5 inhibitor)

c. Biologics

i. Cyramza (Anti-angiogenic)

ii. Vectibix (Muti-kinase inhibitor)

4) References